Business Context and Reporting Period
This Form 8-K is a Current Report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on July 22, 2013. The filing serves as a Regulation FD disclosure regarding the Company's intention to conduct meetings with third parties to present its corporate slide deck.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing solely announces the distribution of a corporate presentation (Exhibit 99.1) to third parties.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to present its corporate slide deck to third parties. The presentation is attached as Exhibit 99.1.
Legal Status of Disclosure: The information disclosed, including the presentation, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It will not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the corporate presentation attached as Exhibit 99.1 for any forward-looking statements or strategic updates.
- Confirm that the registrant is Trovagene, Inc., a Delaware corporation, and not Cardiff Oncology, Inc.
- Note that the disclosure is not considered "filed" under Section 18 of the Exchange Act, limiting its legal liability status compared to standard filings.
- Review the Company's principal executive office address: 11055 Flintkote Avenue, Suite B, San Diego, CA 92121.